权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic

糖胺聚糖相互作用小分子 (GISMO) 作为帕金森病的治疗药物

基本信息

批准号：
9321231
负责人：
Paul Gregor
金额：
$ 14.22万
依托单位：
GISMO THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2019-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9321231
关键词：
Amyloid Animal Model Binding Bioavailable Biological Biological Assay Biological Availability Brain Brain region C57BL/6 Mouse Cell Culture Techniques Cell Death Cell Surface Receptors Cell surface Cells Characteristics Chemicals Collaborations Complex Data Development Disease Disease Progression Drug Kinetics Evaluation GAG Gene Glycosaminoglycans Goals Heparitin Sulfate Hippocampus (Brain)Human Immunohistochemistry In Vitro Injection of therapeutic agent Investigation Label Lead Levodopa Libraries Measures Mediating Nerve Degeneration Neurons Oral Parkinson Disease Patients Pattern Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacy (field)Plasma Property Proteins Reporting Research Institute Rodent Safety Seeds Series Solubility Testing Therapeutic Toxic effect Toxicology Work acute toxicity alpha synuclein analog base cytotoxic cytotoxicity efficacy study experimental study glycosaminoglycan receptor improved in vitro Assay in vivo inhibitor/antagonist lead series motor impairment mouse model neuroblastoma cell neuroprotection novel novel therapeutics olfactory bulb phase 1 study polysulfated glycosaminoglycan pre-clinical preclinical safety prevent programs reduce symptoms screening small molecule small molecule inhibitor symptom treatment synucleinopathy uptake

项目摘要

Glycosaminoglycan-Interacting Small Molecule (GISMO) As Parkinson's Therapeutics ABSTRACT Current approved drugs for Parkinson's Disease (PD) treat the symptoms of the disease but do not stop disease progression. This project is focused on developing a new disease-modifying PD therapeutic with a novel mode of action that is expected to block disease progression. Recent data indicate that heparan sulfate glycosaminoglycans (HS-GAGs) are the receptors responsible for internalization and spreading of alpha-synuclein proteopathic seeds across the CNS. We propose that the inhibition of the HS-GAG-mediated internalization can be achieved by interfering with the interaction between alpha-synuclein and HS-GAGs, and that targeting this interaction will lead to the identification of new treatments for PD and other synucleinopathies. We have previously shown that Glycosaminoglycan-Interacting Small Molecule (GISMO) are a new, structurally-diverse class of compounds that are biologically active in vitro and in vivo and we aim to target the HS-GAG – mediated internalization and aggregation of alpha-synuclein proteopathic seeds with GISMOs. In preliminary work for this project, we screened a library of GISMO-like compounds using a new alpha-synuclein - HS-GAG interaction assay on 96-well plates and identified 15 hit compounds (with inhibitory activity >30%), that have been selected for further development. In the proposed project, we will first screen the 15 hit compounds for inhibition of alpha-synuclein internalization in neuronal cells, and cytotoxic effects. GISMO compounds are expected to inhibit HS-GAG-mediated alpha-synuclein uptake. Lead series of compounds with acceptable efficacy, selectivity and safety in vitro will be then subjected to chemical optimization via medicinal chemistry. The selected 4-5 lead compounds will be evaluated by pharmacokinetics, for oral bioavailability and brain-penetrant properties. Three chosen lead compounds will be subsequently tested in an animal model of Parkinson's Disease, in collaboration with team of Dr. Patrik Brundin (Van Andel Research Institute, Grand Rapids, MI). The successful completion of these studies will enable identifying a Preclinical Candidate for IND-enabling studies. The development of a disease-modifying therapeutic would be the most significant advancement in Parkinson’s disease therapeutics since the development of levodopa in the 1960s.

糖胺聚糖-相互作用小分子（GISMO）作为帕金森病的治疗药物